Published in J Virol on August 01, 1996
The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol (1998) 2.84
The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J Virol (2003) 1.42
Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J Virol (1999) 1.39
Alteration of a single serine in the basic domain of the Epstein-Barr virus ZEBRA protein separates its functions of transcriptional activation and disruption of latency. J Virol (1997) 1.35
The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins. J Virol (1998) 1.31
Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. J Virol (2002) 1.30
Hopping of a processivity factor on DNA revealed by single-molecule assays of diffusion. Proc Natl Acad Sci U S A (2008) 1.21
Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication. J Virol (2004) 1.15
The late promoter of the human cytomegalovirus viral DNA polymerase processivity factor has an impact on delayed early and late viral gene products but not on viral DNA synthesis. J Virol (2007) 1.10
Initiation of Epstein-Barr virus lytic replication requires transcription and the formation of a stable RNA-DNA hybrid molecule at OriLyt. J Virol (2010) 1.09
Interaction with the Epstein-Barr virus helicase targets Zta to DNA replication compartments. J Virol (2001) 1.09
Phosphorylation of Epstein-Barr virus ZEBRA protein at its casein kinase 2 sites mediates its ability to repress activation of a viral lytic cycle late gene by Rta. J Virol (2004) 1.09
Association of human cytomegalovirus proteins IRS1 and TRS1 with the viral DNA polymerase accessory subunit UL44. J Gen Virol (2010) 1.07
Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase. J Virol (2010) 0.99
The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2/3 complex. J Virol (2000) 0.96
Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication. J Virol (2012) 0.95
Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol (2012) 0.95
Interaction of Kaposi's sarcoma-associated herpesvirus ORF59 with oriLyt is dependent on binding with K-Rta. J Virol (2011) 0.92
Spatiotemporally different DNA repair systems participate in Epstein-Barr virus genome maturation. J Virol (2011) 0.91
The Epstein-Barr virus BMRF1 gene is essential for lytic virus replication. J Virol (2006) 0.89
The Epstein-Barr virus protein BMRF1 activates gastrin transcription. J Virol (2005) 0.88
Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer (2016) 0.88
Epstein-Barr virus polymerase processivity factor enhances BALF2 promoter transcription as a coactivator for the BZLF1 immediate-early protein. J Biol Chem (2009) 0.87
Tetrameric ring formation of Epstein-Barr virus polymerase processivity factor is crucial for viral replication. J Virol (2010) 0.87
Endoplasmic reticulum stress causes EBV lytic replication. Blood (2011) 0.86
Phosphoacceptor site S173 in the regulatory domain of Epstein-Barr Virus ZEBRA protein is required for lytic DNA replication but not for activation of viral early genes. J Virol (2007) 0.86
Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells. J Virol (2013) 0.85
Mutations of amino acids in the DNA-recognition domain of Epstein-Barr virus ZEBRA protein alter its sub-nuclear localization and affect formation of replication compartments. Virology (2008) 0.84
Phosphorylation of Kaposi's sarcoma-associated herpesvirus processivity factor ORF59 by a viral kinase modulates its ability to associate with RTA and oriLyt. J Virol (2013) 0.84
Cytomegalovirus replicon-based regulation of gene expression in vitro and in vivo. PLoS Pathog (2012) 0.84
The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins. J Virol (2010) 0.84
A subset of replication proteins enhances origin recognition and lytic replication by the Epstein-Barr virus ZEBRA protein. PLoS Pathog (2010) 0.84
Regulation of Epstein-Barr virus promoters in oral epithelial cells and lymphocytes. J Virol (1999) 0.84
Activation domain requirements for disruption of Epstein-Barr virus latency by ZEBRA. J Virol (1997) 0.83
Initiation of lytic DNA replication in Epstein-Barr virus: search for a common family mechanism. Future Virol (2010) 0.82
Mutations that increase DNA binding by the processivity factor of herpes simplex virus affect virus production and DNA replication fidelity. J Virol (2009) 0.82
Evidence for DNA hairpin recognition by Zta at the Epstein-Barr virus origin of lytic replication. J Virol (2010) 0.81
Regulated transport into the nucleus of herpesviridae DNA replication core proteins. Viruses (2013) 0.78
A Herpesvirus Specific Motif of Epstein-Barr Virus DNA Polymerase Is Required for the Efficient Lytic Genome Synthesis. Sci Rep (2015) 0.78
Trichloromethane fraction of Incarvillea compacta induces lytic cytotoxicity and apoptosis in Epstein-Barr virus-positive gastric cancer AGS cells. BMC Complement Altern Med (2016) 0.75
The SWI/SNF Chromatin Regulator BRG1 Modulates the Transcriptional Regulatory Activity of the Epstein-Barr Virus DNA Polymerase Processivity Factor BMRF1. J Virol (2017) 0.75
Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis. Int J Biol Sci (2016) 0.75
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene (1988) 52.71
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
A gel electrophoresis method for quantifying the binding of proteins to specific DNA regions: application to components of the Escherichia coli lactose operon regulatory system. Nucleic Acids Res (1981) 24.41
Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A (1985) 8.19
Cellular targets for transformation by the adenovirus E1A proteins. Cell (1989) 7.53
Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J (1986) 6.82
Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J (1989) 5.93
Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell (1988) 5.76
Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol (1989) 5.67
trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol (1986) 5.25
The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell (1986) 5.13
Targeting the E1 replication protein to the papillomavirus origin of replication by complex formation with the E2 transactivator. Science (1990) 4.92
Simian virus 40 (SV40) DNA replication: SV40 large T antigen unwinds DNA containing the SV40 origin of replication. Proc Natl Acad Sci U S A (1987) 4.79
Activation of BPV-1 replication in vitro by the transcription factor E2. Nature (1991) 4.51
Transcriptional elements as components of eukaryotic origins of DNA replication. Cell (1988) 4.43
Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol (1990) 4.09
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology (1979) 4.02
Interaction of DNA polymerase alpha-primase with cellular replication protein A and SV40 T antigen. EMBO J (1992) 3.53
The E1 protein of bovine papilloma virus 1 is an ATP-dependent DNA helicase. Proc Natl Acad Sci U S A (1993) 3.26
A DNA binding protein specific for an origin of replication of herpes simplex virus type 1. Proc Natl Acad Sci U S A (1986) 3.24
trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. J Virol (1992) 3.22
The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J (1989) 3.17
An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J Virol (1990) 3.13
Herpes simplex virus DNA replication: the UL9 gene encodes an origin-binding protein. Proc Natl Acad Sci U S A (1988) 3.07
Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. J Virol (1983) 3.06
In vitro transcriptional activation, dimerization, and DNA-binding specificity of the Epstein-Barr virus Zta protein. J Virol (1990) 2.84
The herpes simplex virus type 1 UL42 gene product: a subunit of DNA polymerase that functions to increase processivity. J Virol (1990) 2.79
The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J Virol (1989) 2.65
Identification and mapping of Epstein-Barr virus early antigens and demonstration of a viral gene activator that functions in trans. J Virol (1986) 2.64
Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J Virol (1995) 2.63
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol (1991) 2.58
Tumor initiators and promoters in the induction of Epstein-Barr virus. Proc Natl Acad Sci U S A (1979) 2.55
The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol (1990) 2.49
Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res (1993) 2.38
A general mechanism for transcriptional synergy by eukaryotic activators. Nature (1995) 2.29
The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R. J Virol (1989) 2.20
Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc Natl Acad Sci U S A (1988) 2.12
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol (1994) 2.12
The herpes simplex virus 1 origin binding protein: a DNA helicase. J Biol Chem (1991) 2.11
Acidic transcription factors alleviate nucleosome-mediated repression of DNA replication of bovine papillomavirus type 1. Proc Natl Acad Sci U S A (1994) 1.98
A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. EMBO J (1993) 1.96
DNA looping between the origin of replication of Epstein-Barr virus and its enhancer site: stabilization of an origin complex with Epstein-Barr nuclear antigen 1. Proc Natl Acad Sci U S A (1991) 1.86
Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity. J Virol (1987) 1.84
cis-acting elements in the lytic origin of DNA replication of Epstein-Barr virus. J Virol (1993) 1.80
The Epstein-Barr virus (EBV) early promoter DR contains a cis-acting element responsive to the EBV transactivator EB1 and an enhancer with constitutive and inducible activities. J Virol (1989) 1.79
Evidence for coiled-coil dimer formation by an Epstein-Barr virus transactivator that lacks a heptad repeat of leucine residues. Proc Natl Acad Sci U S A (1990) 1.79
Specific transcription factors stimulate simian virus 40 and polyomavirus origins of DNA replication. Mol Cell Biol (1992) 1.76
Purification of Epstein-Barr virus DNA polymerase from P3HR-1 cells. J Virol (1985) 1.66
Elements in the transcriptional regulatory region flanking herpes simplex virus type 1 oriS stimulate origin function. J Virol (1991) 1.66
Cooperation of EBV DNA polymerase and EA-D(BMRF1) in vitro and colocalization in nuclei of infected cells. Virology (1991) 1.60
Hybridization of Burkitt lymphoblastoid cells. Science (1972) 1.60
A second Epstein-Barr virus early antigen gene in BamHI fragment M encodes a 48- to 50-kilodalton nuclear protein. J Virol (1985) 1.49
Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras. J Virol (1996) 1.47
Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro. J Virol (1993) 1.35
EBNA1 distorts oriP, the Epstein-Barr virus latent replication origin. J Virol (1992) 1.34
The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells. Mol Cell Biol (1992) 1.30
Both the rightward and the leftward open reading frames within the BamHI M DNA fragment of Epstein-Barr virus act as trans-activators of gene expression. J Virol (1987) 1.29
DNA-binding-defective mutants of the Epstein-Barr virus lytic switch activator Zta transactivate with altered specificities. Mol Cell Biol (1994) 1.25
Concatameric replication of Epstein-Barr virus: structure of the termini in virus-producer and newly transformed cell lines. J Virol (1990) 1.21
Demonstration of a stimulatory protein for virus-specified DNA polymerase in phorbol ester-treated Epstein-Barr virus-carrying cells. Proc Natl Acad Sci U S A (1985) 1.18
Functional expression and characterization of the Epstein-Barr virus DNA polymerase catalytic subunit. J Virol (1993) 1.11
Formation of intranuclear replication compartments of Epstein-Barr virus with redistribution of BZLF1 and BMRF1 gene products. Virology (1991) 1.07
Bipartite DNA-binding region of the Epstein-Barr virus BMRF1 product essential for DNA polymerase accessory function. J Virol (1995) 1.02
Physical and functional interaction of the Epstein-Barr virus BZLF1 transactivator with the retinoic acid receptors RAR alpha and RXR alpha. Nucleic Acids Res (1995) 0.96
Functional analysis of EA-D of Epstein-Barr virus. Virology (1995) 0.91
Epstein-Barr virus (EBV) replication and expressions of EA-D (BMRF1 gene product), virus-specific deoxyribonuclease, and DNA polymerase in EBV-activated Akata cells. Virology (1993) 0.87
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Actin depolymerizing factor (ADF/cofilin) enhances the rate of filament turnover: implication in actin-based motility. J Cell Biol (1997) 7.10
Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol (1999) 3.97
Rac homologues and compartmentalized phosphatidylinositol 4, 5-bisphosphate act in a common pathway to regulate polar pollen tube growth. J Cell Biol (1999) 3.69
SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet (1998) 3.51
Ultrahigh resolution Fourier domain optical coherence tomography. Opt Express (2004) 3.26
Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci U S A (1996) 3.13
The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J Virol (1989) 3.11
Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci (2000) 3.03
EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J Virol (1991) 2.70
The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J Virol (1989) 2.65
Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res (1992) 2.62
The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol (1990) 2.49
JC virus enhancer-promoter active in human brain cells. Science (1984) 2.36
Relation between dietary linolenic acid and coronary artery disease in the National Heart, Lung, and Blood Institute Family Heart Study. Am J Clin Nutr (2001) 2.22
Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. Cardiovasc Res (2000) 2.22
Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care (1997) 2.19
Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc Natl Acad Sci U S A (1998) 2.17
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol (1994) 2.12
Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol (1999) 2.09
ATP-dependent interaction of human mismatch repair proteins and dual role of PCNA in mismatch repair. Nucleic Acids Res (1998) 2.09
A redox switch and phosphorylation are involved in the post-translational up-regulation of the adenosine-uridine binding factor by phorbol ester and ionophore. J Biol Chem (1991) 2.09
Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol (2001) 2.07
Clinical results of implantation of the Chirila keratoprosthesis in rabbits. Br J Ophthalmol (1998) 2.02
Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res (2001) 1.98
Tai chi: physiological characteristics and beneficial effects on health. Br J Sports Med (2001) 1.91
The Epstein-Barr virus immediate-early gene product, BMLF1, acts in trans by a posttranscriptional mechanism which is reporter gene dependent. J Virol (1989) 1.86
Kinetic analysis of the interaction of actin-depolymerizing factor (ADF)/cofilin with G- and F-actins. Comparison of plant and human ADFs and effect of phosphorylation. J Biol Chem (1998) 1.85
Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol (2000) 1.77
Sumo-1 modification regulates the DNA binding activity of heat shock transcription factor 2, a promyelocytic leukemia nuclear body associated transcription factor. J Biol Chem (2001) 1.74
ADF proteins are involved in the control of flowering and regulate F-actin organization, cell expansion, and organ growth in Arabidopsis. Plant Cell (2001) 1.71
Alternative end-joining in follicular lymphomas' t(14;18) translocation. Leukemia (2002) 1.71
Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: novel insights into the mechanism of t(14;18) translocation. Blood (2000) 1.70
Quantitative detection of circulating endothelial cells in vasculitis: comparison of flow cytometry and immunomagnetic bead extraction. J Thromb Haemost (2008) 1.61
Acupressure treatment for prevention of postoperative nausea and vomiting. Anesth Analg (1997) 1.58
Angioplasty and bolus urokinase infusion for the restoration of function in thrombosed Brescia-Cimino dialysis fistulas. J Vasc Interv Radiol (1999) 1.58
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene (2007) 1.57
Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res (1999) 1.56
Soccer injury in the lower extremities. Br J Sports Med (2005) 1.53
Lipid metabolism during plant senescence. Prog Lipid Res (1998) 1.48
Identification of an alpha helical motif sufficient for association with papillomavirus E6. J Biol Chem (1998) 1.45
The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. J Virol (1999) 1.41
The spectrum of mutations in TBX3: Genotype/Phenotype relationship in ulnar-mammary syndrome. Am J Hum Genet (1999) 1.41
Population-based screening for rare mutations: high-throughput DNA extraction and molecular amplification from Guthrie cards. Pediatr Res (2001) 1.40
The major surface protein complex of Treponema denticola depolarizes and induces ion channels in HeLa cell membranes. Infect Immun (1996) 1.36
Health care access and preventive care among Vietnamese immigrants: do traditional beliefs and practices pose barriers? Soc Sci Med (1996) 1.35
PIG-M transfers the first mannose to glycosylphosphatidylinositol on the lumenal side of the ER. EMBO J (2001) 1.34
GFP expression in Drosophila tissues: time requirements for formation of a fluorescent product. Dev Biol (1998) 1.30
The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells. Mol Cell Biol (1992) 1.30
Diabetes regulates mitochondrial biogenesis and fission in mouse neurons. Diabetologia (2009) 1.27
RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism. J Virol (1994) 1.27
Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J Virol (2001) 1.27
A comparative structural analysis of the ADF/cofilin family. Proteins (2000) 1.26
A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development. J Intern Med (1999) 1.24
Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study. Hypertension Genetic Epidemiology Network. Am J Hypertens (2001) 1.24
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia (2005) 1.24
Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study. Lancet (2001) 1.23
Human T cells express specific binding sites for C1q. Role in T cell activation and proliferation. J Immunol (1994) 1.22
Identification of survival motor neuron as a transcriptional activator-binding protein. Hum Mol Genet (1999) 1.22
Arachidonoyl ethanolamide-[1,2-14C] as a substrate for anandamide amidase. Life Sci (1995) 1.21
Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol (2001) 1.20
Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene (1992) 1.19
Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (1999) 1.19
Effect of the interval between pregnancies on perinatal outcomes among white and black women. Am J Obstet Gynecol (2001) 1.18
Adult mice with reduced Nurr1 expression: an animal model for schizophrenia. Mol Psychiatry (2007) 1.17
Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol (1995) 1.16
Regional characteristics of sulfur and lead isotope ratios in the atmosphere at several Chinese urban sites. Environ Sci Technol (2001) 1.16
The Zif268 cellular transcription factor activates expression of the Epstein-Barr virus immediate-early BRLF1 promoter. J Virol (1995) 1.15
Identification of plant cytoskeletal, cell cycle-related and polarity-related proteins using Schizosaccharomyces pombe. Plant J (1996) 1.14
Mapping 5' termini of JC virus late RNA. J Virol (1986) 1.13
Age, body mass index, race and other determinants of steroid hormone variability: the HERITAGE Family Study. Eur J Endocrinol (2001) 1.13
Development and clinical assessment of an artificial cornea. Prog Retin Eye Res (2000) 1.13
Influence of hemodynamic factors on rupture of intracranial aneurysms: patient-specific 3D mirror aneurysms model computational fluid dynamics simulation. AJNR Am J Neuroradiol (2011) 1.12
Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol (1997) 1.11
Disparate effects of two herpesvirus [corrected] immediate-early gene trans-activators on the HIV-1 LTR. Virology (1989) 1.11
Genetic and environmental influences on body fat distribution, fasting insulin levels and CVD: are the influences shared? Twin Res (2000) 1.11
Molecular characterisation of the Theileria buffeli/orientalis group. Int J Parasitol (2000) 1.10
Self-assembly of the ionic peptide EAK16: the effect of charge distributions on self-assembly. Biophys J (2004) 1.10
Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther (1999) 1.09
Specific transforming growth factor-beta subtypes regulate embryonic mouse Meckel's cartilage and tooth development. Dev Biol (1994) 1.08
Compact, low-cost Ti:Al2O3 laser for in vivo ultrahigh-resolution optical coherence tomography. Opt Lett (2003) 1.08
Epstein-Barr virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation. J Virol (2001) 1.07
Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc Natl Acad Sci U S A (1993) 1.07
Effect of tai chi exercise on proprioception of ankle and knee joints in old people. Br J Sports Med (2004) 1.06
The cellular YY1 transcription factor binds a cis-acting, negatively regulating element in the Epstein-Barr virus BRLF1 promoter. J Virol (1997) 1.06
Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid. J Pharmacol Toxicol Methods (1995) 1.06
Factors affecting human islet of Langerhans isolation yields. Transplant Proc (2002) 1.06
Potential role for phosphatidic acid in mediating the inflammatory responses to TNF alpha and IL-1 beta. Circ Shock (1994) 1.05
Subclinical central nervous system infection with JC virus in patients with AIDS. J Infect Dis (1992) 1.04
18F-FDG PET/CT findings in patients with Kikuchi disease. Nuklearmedizin (2013) 1.04
The Epstein-Barr virus (EBV) DNA polymerase accessory protein, BMRF1, activates the essential downstream component of the EBV oriLyt. Virology (1997) 1.04